Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and Vinorelbine vs Cisplatin and Pemetrexed in NSCLC With High TS Expression
NCT02919462Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Mar 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vinorelbine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Disease Control Rate at 36 months. Started Mar 2016; status: terminated.
02
Drugs
vinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02919462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919462.